

ANTEO EXTENDS RELATIONSHIP WITH SIGMA-ALDRICH

Highlights

- **Anteo Mix&Go™ product range to be incorporated into Sigma-Aldrich network and online catalog**
- **Inclusion in Sigma-Aldrich range to provide broad access of Anteo products to global markets**

Brisbane, Australia, 22 July 2015 – Anteo Diagnostics (ASX: ADO) is pleased to announce that Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading supplier to diagnostic, clinical research and life science companies worldwide, will incorporate the Anteo Technologies' Mix&Go™ range into its product portfolio.

Under the agreement, Anteo products will be offered through the Sigma-Aldrich network and online catalog, providing Sigma-Aldrich's existing global customer base of more than 1.4 million scientists and technologists access to Mix&Go Reagents, Coupling and Activation Kits. The products will be made available via <http://www.sigmaaldrich.com/> during Q3 of CY15.

Inclusion of Anteo products into the Sigma-Aldrich portfolio follows the successful evaluation of Mix&Go for a variety of applications over the past year at Sigma-Aldrich's labs in St. Louis, Missouri.

"Acceptance of Mix&Go by such a respected party as Sigma-Aldrich provides great commercial validation of Anteo's technology," said Tina Baumgartner, Ph.D., MBA, VP Business Development at Anteo Technologies. "This is an encouraging first step in what is an important relationship, one which is envisaged to generate additional products for sale going forward. We expect sales to build over time. Being included in the Sigma-Aldrich range enables unprecedented access for Anteo into Sigma-Aldrich's key markets, and removes some of the barriers to entry that often occur with a direct sales approach."

-END-

ABOUT ANTEO

Anteo Technologies, a wholly owned subsidiary of Anteo Diagnostics (ASX: ADO), is transforming the way scientists work by providing new, powerful tools developed with their patented Mix&Go™ Activation Reagent that significantly advances traditional assay development methods. Assays produced using Mix&Go can result in reduced development costs and improvements to medical devices and in-vitro diagnostic methods, leading to the earlier detection of disease. <http://anteotech.com>